Literature DB >> 21489168

Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial.

Meredith Borland1, Samantha Milsom, Amanda Esson.   

Abstract

OBJECTIVE: Intranasal fentanyl's (INF) effectiveness is established using highly concentrated INF (HINF). Standard concentration INF (SINF) is more widely available. We aimed to illustrate the equivalence of SINF to HINF.
METHODS: Double-blinded randomized controlled trial was used within a children's hospital ED. Children aged 3-15 years with fractures were randomized to SINF or HINF. Outcome measures included pain scores at time zero and every 10 min until 30 min. Additional analgesic agents were noted.
RESULTS: Data in 189 children (91 HINF, 98 SINF) were obtained. Pre-analgesia median VAS was 80.0 mm (interquartile range [IQR] 60.0-95.5) in SINF, 77.5 mm (IQR 60.0-100) in HINF. At 10 min median VAS was 49.5 mm (IQR 26.5-68.5) and 43.0 mm (IQR 15.2-66.0), respectively, at 20 min 27.5 mm (IQR 18.5-56.5) and 35.0 mm (IQR 9.0-57.0) and at 30 min 20.0 mm (IQR 10.0-46.0) and 21.5 mm (IQR 4.75-51.0). Each agent demonstrated significant decrease in pain scores (median decrease 40 mm, P = 0.000). Additional analgesia was given in 67 (42 SINF, 25 HINF) (P = 0.028). The decrease in pain scores between children < and ≥50 kg in SINF was significant both overall (P = 0.005) and between 10 and 20 min (P = 0.003). There was no difference in HINF at any time by weight.
CONCLUSIONS: The two concentrations of INF were equivalent in reducing pain, with a trend to increased oral additional agents in the more dilute solution. The widespread use of this readily available analgesic in the standard concentration can be supported, particularly in patients <50 kg.
© 2011 The Authors. EMA © 2011 Australasian College for Emergency Medicine and Australasian Society for Emergency Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21489168     DOI: 10.1111/j.1742-6723.2011.01391.x

Source DB:  PubMed          Journal:  Emerg Med Australas        ISSN: 1742-6723            Impact factor:   2.151


  3 in total

1.  Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain.

Authors:  Sebastiano Mercadante; Renato Vellucci; Arturo Cuomo; Claudio Adile; Andrea Cortegiani; Alessandro Valle; Patrizia Villari; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2014-10-29       Impact factor: 3.603

2.  Pediatric Sedation and Analgesia Outside the Operating Room: Combining Intranasal Fentanyl and Inhaled Nitrous Oxide.

Authors:  Julia Hoeffe; Regina G Vogel; Roland A Ammann
Journal:  J Pediatr Pharmacol Ther       Date:  2022-07-06

Review 3.  Intranasal fentanyl for the management of acute pain in children.

Authors:  Adrian Murphy; Ronan O'Sullivan; Abel Wakai; Timothy S Grant; Michael J Barrett; John Cronin; Siobhan C McCoy; Jeffrey Hom; Nandini Kandamany
Journal:  Cochrane Database Syst Rev       Date:  2014-10-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.